Core Insights - The company experienced significant growth in H1 2025, primarily due to a turnaround in investment income and revenue from the acquisition of Shenzhen JianYuan in the pharmaceutical sector [1][2]. Financial Performance - Adjusted revenue and net profit for H1 2025 were 665 million and 129 million yuan, respectively, reflecting year-on-year increases of 65% and 13% [2]. - Investment income, including investment gains and fair value changes, reached 36 million yuan, recovering from a negative 79 million yuan in the same period of 2024 [2]. - Private equity management fee income decreased by 5.07% to 210 million yuan, while revenue from the building materials segment grew by 4.88% to 274 million yuan [2]. - Revenue from the biopharmaceutical segment was 145 million yuan, driven by the acquisition of Shenzhen JianYuan, which contributed to both business and investment income growth [2]. Strategic Moves - The acquisition of Shenzhen JianYuan represents a deepened commitment to the biopharmaceutical industry, focusing on the research and sales of peptide products, which is expected to drive future revenue growth [3]. - The company is also looking to enhance its project portfolio by focusing on innovative technology sectors such as new industrialization and artificial intelligence [3]. Market Outlook - Recent improvements in the capital market are favorable for the company's project exits, which will accelerate the realization of returns from follow-on investments and performance compensation [3][4].

证券代码：688117 证券简称：圣诺生物 公告编号：2025-019 成都圣诺生物科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 公司紧跟多肽行业发展趋势，持续拓展国内外营销市场，加大产品销售力度。 净利润同比显著提升。 四、风险提示 经注册会计师审计。 （二）业绩预告情况 （1）经财务部门初步测算，成都圣诺生物科技股份有限公司（以下简称"公 司"）预计 2025 年半年度实现归属于母公司所有者的净利润 7,702.75 万元至 增加 253.54%至 332.10%。 （2）预计 2025 年半年度实现归属于母公司所有者的扣除非经常性损益的净 利润 7,734.64 万元至 9,453.45 万元，与上年同期相比，将增加 5,822.44 万元 至 7,541.25 万元，同比增加 304.49%至 394.38%。 （三）本次业绩预告未经注册会计师审计。 二、上年同期业绩情况 公司上年同期归属于母公司所有者的净利润为 2,178.76 万元，归属于母公 司所有者扣除非经常性损益 ...